News, features, and commentary about cancer-related issues ...

A new research paper was published in Volume 13 of Oncoscience on February 7, 2026, titled “Reduced immunogenicity of MYC amplified, metastatic prostate cancer.” ...

John Tesh reveals how wife Connie Sellecca saved his life during prostate cancer battle. The former TV host credits faith and marriage for survival.

MYC amplification is associated with reduced tumor immunogenicity as assessed by the recovery of IR recombination reads from prostate cancer genomics ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

In this retrospective study, researchers sought to determine the efficacy, safety, and effectiveness of a reduced ARSI dose compared to a full dose in non-metastatic castration-resistant prostate ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

Manufacturing optimization is projected to expand batch output by ~50%, improving supply reliability and supporting higher-throughput PSMA PET imaging services. Increased radioactivity extends shelf ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...